368 related articles for article (PubMed ID: 35848888)
1. Mechanisms of resistance to immune checkpoint inhibitors.
Nagasaki J; Ishino T; Togashi Y
Cancer Sci; 2022 Oct; 113(10):3303-3312. PubMed ID: 35848888
[TBL] [Abstract][Full Text] [Related]
2. Resistance to immune checkpoint inhibitors and the tumor microenvironment.
Kawashima S; Togashi Y
Exp Dermatol; 2023 Mar; 32(3):240-249. PubMed ID: 36437644
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
Wang Z; Wang Y; Gao P; Ding J
Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
[TBL] [Abstract][Full Text] [Related]
4. Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions.
Zhang C; Zhang C; Wang H
Cancer Lett; 2023 May; 562():216182. PubMed ID: 37076040
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
[TBL] [Abstract][Full Text] [Related]
6. Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment.
Gao Z; Bai Y; Lin A; Jiang A; Zhou C; Cheng Q; Liu Z; Chen X; Zhang J; Luo P
Mol Cancer; 2023 Feb; 22(1):31. PubMed ID: 36793048
[TBL] [Abstract][Full Text] [Related]
7. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies.
Atkins MB; Ascierto PA; Feltquate D; Gulley JL; Johnson DB; Khushalani NI; Sosman J; Yap TA; Kluger H; Sullivan RJ; Tawbi H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918225
[TBL] [Abstract][Full Text] [Related]
8. Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy.
Li H; Zhao A; Li M; Shi L; Han Q; Hou Z
Front Immunol; 2022; 13():1046755. PubMed ID: 36569893
[TBL] [Abstract][Full Text] [Related]
9. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
10. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
[TBL] [Abstract][Full Text] [Related]
11. Reversing resistance to immune checkpoint inhibitor by adding recombinant human adenovirus type 5 in a patient with small cell lung cancer with promoted immune infiltration: a case report.
Zhao Q; Tong J; Liu X; Li S; Chen D; Miao L
J Cancer Res Clin Oncol; 2022 May; 148(5):1269-1273. PubMed ID: 35212817
[TBL] [Abstract][Full Text] [Related]
12. Determinants of Resistance to Checkpoint Inhibitors.
Tran L; Theodorescu D
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111080
[TBL] [Abstract][Full Text] [Related]
13. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Naimi A; Mohammed RN; Raji A; Chupradit S; Yumashev AV; Suksatan W; Shalaby MN; Thangavelu L; Kamrava S; Shomali N; Sohrabi AD; Adili A; Noroozi-Aghideh A; Razeghian E
Cell Commun Signal; 2022 Apr; 20(1):44. PubMed ID: 35392976
[TBL] [Abstract][Full Text] [Related]
14. Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines.
Oladejo M; Paulishak W; Wood L
Semin Cancer Biol; 2023 Jan; 88():81-95. PubMed ID: 36526110
[TBL] [Abstract][Full Text] [Related]
15. Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance.
Weng CY; Kao CX; Chang TS; Huang YH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33514004
[TBL] [Abstract][Full Text] [Related]
16. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer.
Muaibati M; Abuduyilimu A; Zhang T; Dai Y; Li R; Huang F; Li K; Tong Q; Huang X; Zhuang L
Expert Rev Mol Med; 2023 Jan; 25():e6. PubMed ID: 36691778
[TBL] [Abstract][Full Text] [Related]
18. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
19. Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need.
Hu-Lieskovan S; Malouf GG; Jacobs I; Chou J; Liu L; Johnson ML
Future Oncol; 2021 Apr; 17(11):1401-1439. PubMed ID: 33475012
[TBL] [Abstract][Full Text] [Related]
20. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]